Zaltrap
aflibercept
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Zaltrap. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zaltrap.
For practical information about using Zaltrap, patients should read the package leaflet or contact their doctor or pharmacist.
This EPAR was last updated on 12/11/2019
Authorisation details
Product details | |
---|---|
Name |
Zaltrap
|
Agency product number |
EMEA/H/C/002532
|
Active substance |
aflibercept
|
International non-proprietary name (INN) or common name |
aflibercept
|
Therapeutic area (MeSH) |
Colorectal Neoplasms
|
Anatomical therapeutic chemical (ATC) code |
L01XX44
|
Publication details | |
---|---|
Marketing-authorisation holder |
Sanofi-Aventis Groupe
|
Revision |
8
|
Date of issue of marketing authorisation valid throughout the European Union |
01/02/2013
|
Contact address |
Product information
30/10/2019 Zaltrap - EMEA/H/C/002532 - IAIN/0052
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Therapeutic indication
Treatment of metastatic colorectal cancer (MCRC).